Abemaciclib (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Abemaciclib" in English language version.

refsWebsite

Global rank English rank

11clinicaltrials.gov

5,225^th place

4,062^nd place

10nih.gov

4^th place

7web.archive.org

1^st place

7doi.org

2^nd place

3fda.gov

447^th place

338^th place

1tga.gov.au

3,984^th place

2,622^nd place

1hres.ca

low place

1europa.eu

68^th place

117^th place

1lww.com

2,769^th place

3,314^th place

1drugs.com

399^th place

333^rd place

1s3-us-west-2.amazonaws.com

low place

1semanticscholar.org

11^th place

8^th place

1ascopost.com

low place

ascopost.com

"LY2835219 Shows Strong Single-Agent Activity in Preliminary Study in Metastatic Breast Cancer". Archived from the original on 18 September 2015. Retrieved 8 January 2016.

clinicaltrials.gov

"SARC041: Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma". www.clinicaltrials.gov. Retrieved 20 July 2023.
"A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (CYCLONE 3)". www.clinicaltrials.gov. Retrieved 20 July 2023.
"Immune Modulation by Abemaciclib in HNSCC. (AIM Trial)". www.clinicaltrials.gov. Retrieved 20 July 2023.
"A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma". www.clinicaltrials.gov. Retrieved 20 July 2023.
"Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors". www.clinicaltrials.gov. Retrieved 20 July 2023.
"Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors (AflacST1501)". www.clinicaltrials.gov. Retrieved 20 July 2023.
"Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6". www.clinicaltrials.gov. Retrieved 20 July 2023.
"Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas". www.clinicaltrials.gov. Retrieved 20 July 2023.
"Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma". www.clinicaltrials.gov. Retrieved 20 July 2023.
"A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma". www.clinicaltrials.gov. Retrieved 20 July 2023.
"Study of LY2835219 for Mantle Cell Lymphoma". www.clinicaltrials.gov. Retrieved 20 July 2023.

doi.org

Lu J (August 2015). "Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer". Journal of Hematology & Oncology. 8 (1): 98. doi:10.1186/s13045-015-0194-5. PMC 4534142. PMID 26264704.
Goodrich DW, Wang NP, Qian YW, Lee EY, Lee WH (October 1991). "The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle". Cell. 67 (2): 293–302. doi:10.1016/0092-8674(91)90181-w. PMID 1655277. S2CID 12990398.
Hino H, Iriyama N, Kokuba H, et al. (June 2020). "Abemaciclib induces atypical cell death in cancer cells characterized by formation of cytoplasmic vacuoles derived from lysosomes". Cancer Sci. 111 (6): 2132–2145. doi:10.1111/cas.14419. PMC 7293084. PMID 32304130.
Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, et al. (September 2017). "MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR⁺/HER2⁻ Metastatic Breast Cancer". Clinical Cancer Research. 23 (17): 5218–5224. doi:10.1158/1078-0432.CCR-17-0754. PMC 5581697. PMID 28533223.{{cite journal}}: CS1 maint: overridden setting (link)
Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. (September 2017). "MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy". Journal of Clinical Oncology. 35 (25): 2875–2884. doi:10.1200/JCO.2017.73.7585. PMID 28580882.{{cite journal}}: CS1 maint: overridden setting (link)
Royce M, Osgood C, Mulkey F, Bloomquist E, Pierce WF, Roy A, et al. (April 2022). "FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer". Journal of Clinical Oncology. 40 (11): 1155–1162. doi:10.1200/JCO.21.02742. PMC 8987222. PMID 35084948.{{cite journal}}: CS1 maint: overridden setting (link)
Frederick MO, Kjell DP (February 2015). "A synthesis of abemaciclib utilizing a Leuckart–Wallach reaction". Tetrahedron Letters. 56 (7): 949–951. doi:10.1016/j.tetlet.2014.12.082.

drugs.com

Drugs.com: Abemaciclib Monograph. Accessed 22 November 2017.

europa.eu

ema.europa.eu

"Verzenios EPAR". European Medicines Agency. 27 September 2018. Retrieved 17 June 2024.

fda.gov

"FDA approves new treatment for certain advanced or metastatic breast cancers" (Press release). Food and Drug Administration. 28 September 2017. Archived from the original on 23 April 2019. Retrieved 29 September 2017.
Center for Drug Evaluation and Research (9 February 2019). "FDA approves abemaciclib for HR-positive, HER2-negative breast cancer". FDA.
Center for Drug Evaluation and Research (24 March 2023). "FDA D.I.S.C.O. Burst Edition: FDA approval of Verzenio (abemaciclib) with endocrine therapy for patients with HR-positive, HER2-negative, node-positive, early breast cancer". FDA. Archived from the original on 30 May 2023.

hres.ca

hpr-rps.hres.ca

"Summary Basis of Decision (SBD) for Verzenio". Health Canada. 23 October 2014. Archived from the original on 31 May 2022. Retrieved 29 May 2022.

lww.com

journals.lww.com

Digiulio S (8 October 2015). "FDA's Breakthrough Therapy Designation to Abemaciclib for Breast Cancer". Oncology Times. LWW Journals. Archived from the original on 4 June 2021. Retrieved 30 March 2016.

nih.gov

pubmed.ncbi.nlm.nih.gov

Lu J (August 2015). "Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer". Journal of Hematology & Oncology. 8 (1): 98. doi:10.1186/s13045-015-0194-5. PMC 4534142. PMID 26264704.
Goodrich DW, Wang NP, Qian YW, Lee EY, Lee WH (October 1991). "The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle". Cell. 67 (2): 293–302. doi:10.1016/0092-8674(91)90181-w. PMID 1655277. S2CID 12990398.
Hino H, Iriyama N, Kokuba H, et al. (June 2020). "Abemaciclib induces atypical cell death in cancer cells characterized by formation of cytoplasmic vacuoles derived from lysosomes". Cancer Sci. 111 (6): 2132–2145. doi:10.1111/cas.14419. PMC 7293084. PMID 32304130.
Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, et al. (September 2017). "MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR⁺/HER2⁻ Metastatic Breast Cancer". Clinical Cancer Research. 23 (17): 5218–5224. doi:10.1158/1078-0432.CCR-17-0754. PMC 5581697. PMID 28533223.{{cite journal}}: CS1 maint: overridden setting (link)
Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. (September 2017). "MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy". Journal of Clinical Oncology. 35 (25): 2875–2884. doi:10.1200/JCO.2017.73.7585. PMID 28580882.{{cite journal}}: CS1 maint: overridden setting (link)
Royce M, Osgood C, Mulkey F, Bloomquist E, Pierce WF, Roy A, et al. (April 2022). "FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer". Journal of Clinical Oncology. 40 (11): 1155–1162. doi:10.1200/JCO.21.02742. PMC 8987222. PMID 35084948.{{cite journal}}: CS1 maint: overridden setting (link)

ncbi.nlm.nih.gov

Lu J (August 2015). "Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer". Journal of Hematology & Oncology. 8 (1): 98. doi:10.1186/s13045-015-0194-5. PMC 4534142. PMID 26264704.
Hino H, Iriyama N, Kokuba H, et al. (June 2020). "Abemaciclib induces atypical cell death in cancer cells characterized by formation of cytoplasmic vacuoles derived from lysosomes". Cancer Sci. 111 (6): 2132–2145. doi:10.1111/cas.14419. PMC 7293084. PMID 32304130.
Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, et al. (September 2017). "MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR⁺/HER2⁻ Metastatic Breast Cancer". Clinical Cancer Research. 23 (17): 5218–5224. doi:10.1158/1078-0432.CCR-17-0754. PMC 5581697. PMID 28533223.{{cite journal}}: CS1 maint: overridden setting (link)
Royce M, Osgood C, Mulkey F, Bloomquist E, Pierce WF, Roy A, et al. (April 2022). "FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer". Journal of Clinical Oncology. 40 (11): 1155–1162. doi:10.1200/JCO.21.02742. PMC 8987222. PMID 35084948.{{cite journal}}: CS1 maint: overridden setting (link)

s3-us-west-2.amazonaws.com

"Highlights of Prescribing Information for Verzenio" (PDF). September 2017. Archived (PDF) from the original on 5 September 2021. Retrieved 22 November 2017.

semanticscholar.org

api.semanticscholar.org

Goodrich DW, Wang NP, Qian YW, Lee EY, Lee WH (October 1991). "The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle". Cell. 67 (2): 293–302. doi:10.1016/0092-8674(91)90181-w. PMID 1655277. S2CID 12990398.

tga.gov.au

"Verzenio (Eli Lilly Australia Pty Ltd)". Therapeutic Goods Administration (TGA). 28 September 2022. Archived from the original on 18 March 2023. Retrieved 9 April 2023.

web.archive.org

"Verzenio (Eli Lilly Australia Pty Ltd)". Therapeutic Goods Administration (TGA). 28 September 2022. Archived from the original on 18 March 2023. Retrieved 9 April 2023.
"Summary Basis of Decision (SBD) for Verzenio". Health Canada. 23 October 2014. Archived from the original on 31 May 2022. Retrieved 29 May 2022.
Digiulio S (8 October 2015). "FDA's Breakthrough Therapy Designation to Abemaciclib for Breast Cancer". Oncology Times. LWW Journals. Archived from the original on 4 June 2021. Retrieved 30 March 2016.
"FDA approves new treatment for certain advanced or metastatic breast cancers" (Press release). Food and Drug Administration. 28 September 2017. Archived from the original on 23 April 2019. Retrieved 29 September 2017.
"Highlights of Prescribing Information for Verzenio" (PDF). September 2017. Archived (PDF) from the original on 5 September 2021. Retrieved 22 November 2017.
"LY2835219 Shows Strong Single-Agent Activity in Preliminary Study in Metastatic Breast Cancer". Archived from the original on 18 September 2015. Retrieved 8 January 2016.
Center for Drug Evaluation and Research (24 March 2023). "FDA D.I.S.C.O. Burst Edition: FDA approval of Verzenio (abemaciclib) with endocrine therapy for patients with HR-positive, HER2-negative, node-positive, early breast cancer". FDA. Archived from the original on 30 May 2023.